Researchers reported that CAR‑macrophage therapy reduced liver fibrosis in mouse models, providing a proof‑of‑concept for engineered innate immune cells as anti‑fibrotic agents. The study showed decreased collagen deposition and improved liver function after targeted delivery of CAR‑modified macrophages. CAR‑macrophage therapy repurposes principles from CAR‑T technology to reprogram macrophage phagocytosis and remodeling in fibrotic tissue. The authors highlight antigen selection, macrophage persistence and safety profiling as key translational hurdles. If reproduced in larger animal models, the approach could open a new therapeutic class for fibrotic diseases where few disease‑modifying drugs exist, but manufacturing, delivery and on‑target off‑tissue activity will require careful clinical translation.